top of page

Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines. He also describes Frontier's platform and a recent $80M series C raise.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page